CD274 and neoplasm: Several studies have shown the usefulness of PD-L1 expression in tumor cells [5,6], the amount of gene mutations in tumor [7], and lymphocytes that migrate to the cancer microenvironment [8] as biomarkers for selecting patients who are sensitive to cancer immunotherapy.